After diabetic retinopathy, the varieties of retinal vein occlusion constitute the most prevalent category of retinal vascular disease. For macular edema associated with central retinal vein occlusion (CRVO), no effective therapy existed until 2009, despite decades of research and failed pilot therapies. This comprehensive, illustrated text integrates recent advances in treatments with the parallel progress in understanding of disease mechanisms. Complete with case studies, this text is perfect for retina specialists, ophthalmologists, optometrists, and residents and fellows in these fields.
After diabetic retinopathy, retinal vein occlusions are the most common retinal vascular disease. This comprehensive, illustrated text includes case studies, integrating advances in treatments with progress in understanding the mechanisms of these occlusions.
?
After diabetic retinopathy, the varieties of retinal vein occlusion (central, hemi-central, and branch) constitute the most prevalent category of retinal vascular disease. For macular edema associated with central retinal vein occlusion (CRVO), no effective therapy existed until 2009 despite decades of research and failed pilot therapies. In 2009, serial intravitreal triamcinolone therapy was proven to be effective compared to observation. In 2010, a randomized controlled trial reported that laser anastomosis was associated with improved vision relative to observation. For iris neovascularization associated with CRVO, laser panretinal photocoagulation has been proven to be effective at reducing neovascular glaucoma since 1995 and intraocular anti-VEGF drug injections for short term regression of iris neovascularization since 2005. For macular edema associated with branch retinal vein occlusion (BRVO), grid laser photocoagulation was proven to have modest benefits compared to observation since 1988. Sector panretinal photocoagulation for retinal neovascularizal³